1. Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial 
Michael M.B. Green, MD, Mitchell E. Horwitz, MD, Yubin Kang, MD, Nelson J. Chao, MD, Gwynn D. Long, MD, David Rizzieri, M.D., Cristina Gasparetto, MD, Anthony D. Sung, MD, Stefanie Sarantopoulos, MD, PhD, Zhiguo Li, PhD, Kelly Corbet, Emily Riggan-Stuelke, Keith Sullivan, MD, Beth Wilson, Saurabh Chhabra, MD, Luciano V. Costa, MD, Alice Mims, Robert Stuart, MD 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 2, Pages S31-S32 (February 2015)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1 Cumulative incidence: time to ANC >500.
Biology of Blood and Marrow Transplantation  , S31-S32DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Figure 2 Cumulative incidence: time to platelet >20.
Biology of Blood and Marrow Transplantation  , S31-S32DOI: ( /j.bbmt )
Copyright © Terms and Conditions